Navigation Links
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Date:4/1/2008

mation available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Pegasys(R) and Copegus(R) are registered trademarks of Roche


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of Phase 1b Trial of ITMN-191
2. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
3. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
4. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
5. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com . ... logo are considered trademarks of PDL BioPharma, Inc. ... release contains forward-looking statements. Each of these forward-looking statements ... from those, express or implied, in these forward-looking statements. ...
Cached Medicine Technology:Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of its ... and coolest applications on the market for iOS, Android, ... technology expert, conducted the app review and shared with ... with knights, nature, and peasants. , The first ... Eurogamer. The popularity of these games grew over the ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
(Date:3/28/2015)... 2015 India Network visitor health ... available to all visitors who purchase the plan before ... are encouraged to purchase the insurance program as soon ... proper coverage for pre-existing medical conditions. Parents and grandparents ... medical conditions with serious consequences to their health. Many ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... Nov. 4 Online community member Emimi shares the ... that the support of an online community and talking to others ... related challenges. When she finally did become pregnant, she wanted to ... so by logging on to the My Community section of ...
... ST. PAUL, Minn., Nov. 4 The H1N1 strain may ... school nurses in Minnesota who are celebrating 100 years of ... Friday, November 6th will honor the ten decades of valuable ... and communities. , Never ones to miss an ...
... Nov. 4 The United States and the Commonwealth ... suit in the Western District of Virginia against the ... and Keystone Education and Youth Services LLC, the Justice ... Marion Youth Center, a residential facility in Marion, Va., ...
... patients on the heart-lung machine improved survival, study found ... for people who had coronary bypass surgery "off-pump," meaning ... than for those undergoing the conventional procedure, a major ... in 10 patients getting the off-pump procedure had died, ...
... WAYNE, Pa., Nov. 4 Qualsec (OTC Bulletin Board: QLSZ; ... Dr Robi Ludwig, Psy.D., a nationally known psychotherapist and award ... Dr Ludwig will make appearances, on behalf of VitaminSpice, on ... News Talk Shows and satellite radio stations. , Dr ...
... KNDL ), a leading, global full-service clinical research organization, today ... diluted share for the third quarter of 2009, primarily the ... with net income of $9.4 million or $0.62 per diluted ... forma basis, excluding the additional non-cash interest and restructuring charge, ...
Cached Medicine News:Health News:Regence's Social Media Web Site Gets a Facelift 2Health News:The Minnesota Nurses Association: School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 2Health News:United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 3Health News:Nationally Known Psychotherapist Dr. Robi Ludwig Joins Qualsec's Wholly-Owned Subsidiary VitaminSpice 2Health News:Kendle Announces Third Quarter 2009 Results 2Health News:Kendle Announces Third Quarter 2009 Results 3Health News:Kendle Announces Third Quarter 2009 Results 4Health News:Kendle Announces Third Quarter 2009 Results 5Health News:Kendle Announces Third Quarter 2009 Results 6Health News:Kendle Announces Third Quarter 2009 Results 7Health News:Kendle Announces Third Quarter 2009 Results 8Health News:Kendle Announces Third Quarter 2009 Results 9Health News:Kendle Announces Third Quarter 2009 Results 10
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: